Cellebrite DI Ltd. (NASDAQ:CLBT) Receives $24.00 Consensus Target Price from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been given a consensus rating of “Moderate Buy” by the five brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $24.00.

A number of analysts have issued reports on CLBT shares. Bank of America raised their target price on Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Needham & Company LLC raised their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Lake Street Capital lifted their target price on shares of Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Wall Street Zen lowered shares of Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 22nd.

Hedge Funds Weigh In On Cellebrite DI

Several large investors have recently modified their holdings of the business. Financial Management Professionals Inc. purchased a new position in shares of Cellebrite DI during the 3rd quarter worth $28,000. CWM LLC lifted its position in Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after buying an additional 720 shares during the last quarter. Signaturefd LLC boosted its stake in Cellebrite DI by 68.3% during the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after buying an additional 819 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Cellebrite DI by 1,998.0% during the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after acquiring an additional 1,998 shares during the last quarter. Finally, Toth Financial Advisory Corp purchased a new stake in shares of Cellebrite DI in the 3rd quarter valued at approximately $38,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Price Performance

CLBT opened at $18.24 on Tuesday. The firm has a market capitalization of $4.37 billion, a price-to-earnings ratio of 58.84, a price-to-earnings-growth ratio of 3.14 and a beta of 1.29. The company’s 50 day simple moving average is $17.72 and its two-hundred day simple moving average is $16.74. Cellebrite DI has a 1-year low of $13.10 and a 1-year high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.05). Cellebrite DI had a net margin of 16.74% and a return on equity of 20.81%. The company had revenue of $126.03 million during the quarter, compared to analyst estimates of $122.98 million. During the same period in the prior year, the business posted $0.14 EPS. Cellebrite DI’s revenue for the quarter was up 17.9% compared to the same quarter last year. On average, equities analysts anticipate that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.